Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the ...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)是一家临床阶段生物技术公司，目前股价为每股16.43美元。该公司宣布了2024年年度股东大会的结果，并提供了与Palvella Therapeutics, Inc.计划合并的最新进展。根据 InvestingPro 的数据，该公司在过去十二个月面临重大挑战，收入下降97%，但仍保持较强的流动性，流动比率为4.82。

David Pieris Motor Company (Lanka) Limited (DPMC) announces the launch of the Bajaj PulsarN160, the third motorcycle model produced under the Local Value Addition (LVA) programme.

BOSTON, MA / ACCESSWIRE / April 19, 2024 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) today announced that its Board of Directors has approved a 1-for-80 reverse stock split of the Company's ...

Pieris Pharmaceuticals Inc. PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of $2.19.

BOSTON (AP) — BOSTON (AP) — Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a ...

*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

German startup Pieris hopes they could prove a cheaper alternative to antibodies. (Click here for company profile.) The structure of lipocalins was first elucidated during the early 1980s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...